drugset

drugset / Trial / NCT02667236

A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.

NCT02667236 ↗

Phase 3 Completed 450 enrolled Aclaris Therapeutics, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-blind, vehicle-controlled, parallel group study of A-101 Solution 40% compared with Vehicle Solution.

Timeline

Start: 2016-01
Primary completion: 2016-10
Completion: 2016-10

Publications

Smith SR, Xu S, Estes E, Shanler SD. Anatomic Site-Specific Treatment Response With 40% Hydrogen Peroxide (w/w) Topical Formulation for Raised Seborrheic Keratoses: Pooled Analysis of Data from Two Phase 3 Studies. J Drugs Dermatol. 2018 Oct 1;17(10):1092-1098.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Hydrogen Peroxide	Small molecule	40 %	Topical

Indications